Filtered By:
Infectious Disease: Endemics
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 382 results found since Jan 2013.
Microbiological profile in chronic granulomatous disease patients in a single Brazilian primary immunodeficiencies center
CONCLUSION: Staphylococcus sp., Staphylococcus aureus, and Aspergillus sp. were the most frequent agents in this cohort. M. tuberculosis should be considered in endemic areas. Detection of infectious agents drives to find adequate treatment and benefits the evolution of patients with CGD.PMID:34224228 | DOI:10.15586/aei.v49i4.202
Source: Allergologia et Immunopathologia - July 5, 2021 Category: Allergy & Immunology Authors: Aim ée Filippini Bifulco Oliveira Antonio Carlos Pastorino Mayra de Barros Dorna Ana Paula Beltran Moschione Castro Jos é Roberto Mendes Pegler Beni Morgenstern Magda Maria Sales Carneiro-Sampaio Source Type: research
Investigational malaria vaccine gives strong, lasting protection
(NIH/National Institute of Allergy and Infectious Diseases) Two U.S. Phase 1 clinical trials of a novel candidate malaria vaccine have found that the regimen conferred unprecedentedly high levels of durable protection when volunteers were later exposed to disease-causing malaria parasites. The vaccine combines live parasites with either of two widely used antimalarial drugs -- an approach termed chemoprophylaxis vaccination. A Phase 2 clinical trial of the vaccine is now underway in Mali, a malaria-endemic country.
Source: EurekAlert! - Infectious and Emerging Diseases - June 30, 2021 Category: Infectious Diseases Source Type: news
The U.S. Government Placed a Big Bet on an Antiviral Pill to Fight COVID-19
We’re not going to vaccinate our way completely out of this pandemic. With epidemiologists around the world increasingly accepting the reality that SARS-CoV-2 and its variants will become endemic viruses—like the seasonal flu—the push is on to develop antiviral medications that can be taken at home to prevent infections from leading to hospitalization and death. Today, the Department of Health and Human Services announced that the Biden Administration has authorized $3.2 billion to accelerate the development of antivirals already in the R&D pipeline, with the hope that at least one will be ready for r...
Source: TIME: Health - June 17, 2021 Category: Consumer Health News Authors: Jeffrey Kluger Tags: Uncategorized COVID-19 Source Type: news
